期刊
OPEN LIFE SCIENCES
卷 17, 期 1, 页码 1-9出版社
DE GRUYTER POLAND SP Z O O
DOI: 10.1515/biol-2022-0002
关键词
dabigatran; rivaroxaban; anticoagulants; thrombin; APC
类别
资金
- Key Special Project of Pudong New Area Health System [PWZzk2017-23]
This study examined the effects of dabigatran and rivaroxaban on the activities of coagulation factors. The results showed that low doses of dabigatran inhibited activated protein C (APC) activity, while high doses of dabigatran and rivaroxaban inhibited the activities of several coagulation factors, with a more significant effect at higher drug concentrations.
The aim of this study was to explore the effects of dabigatran and rivaroxaban on the activities of various coagulation factors. To achieve that, 60 rabbits were randomly divided into experimental groups that received different doses of dabigatran or rivaroxaban. The effects of dabigatran and rivaroxaban on the activities of FII, FV, FVIII, FX, and activated protein C (APC) were analyzed. In the dabigatran groups, activated partial thromboplastin time and thromboplastin time (TT) were prolonged after drug administration, and the activities of FII, FV, FVIII, and FX were inhibited as the drug concentration increased. Low doses of dabigatran inhibited APC activity. In the rivaroxaban groups, APTT and TT were not significantly prolonged after drug administration. In contrast, the high-dose rivaroxaban group exhibited prolonged PT, and the degree of inhibition of the activities of FII, FV, FVIII, and FX increased as the drug concentration increased. Rivaroxaban had no significant effect on APC activity regardless of dosage. As the drug concentration increased, both NOACs had more significant inhibitory effects on the activities of FII, FV, FVIII, and FX. Low concentrations of dabigatran generated an inhibitory effect on APC activity, while high concentrations of dabigatran had no significant effect. Rivaroxaban had no significant effect on APC activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据